cancer%20pain
CANCER PAIN
Cancer pain is an unpleasant sensory & emotional experience due to actual or potential tissue damage in patients with cancer.
Effective pain management in cancer patients with pain is an essential part of oncologic management due to increasing evidence of survival.
Pancreatic, head & neck cancer has a high prevalence of cancer pain.
During initial evaluation, follow-ups and new therapy initiation of patients with cancer, it is essential that they will be screened & evaluated for pain.

Cancer Pain Drug Information

Drug Information

Indication: Moderate to severe acute & chronic pain & in painful diagnostic measure & surgery.

Indication: Relief of fever & mild to moderate pain including headache, dental pain, post-op pain, dysmenorrhoea; musc...

Indication: Major depressive disorder, generalized anxiety disorder. Management of diabetic peripheral neuropathic pain.

Indication: Primary dysmenorrhea & relief of moderate pain when therapy will not exceed 1 wk.

Indication: Mild to moderate muscular, traumatic & dental pain, headache, post-op & post-partum pain, RA (includin...

Indication: Adjunctive therapy in partial seizures w/ & w/o secondary generalization in adults & childn ≥3 yr. ...

Indication: Short-acting analgesia in surgical procedures. Adjunct in general anaesth maintenance. In combination w/ neuro...

Indication: Mild to moderate pain, rheumatic disorders, dysmenorrhoea, menorrhagia.

Indication: Symptomatic relief of RA eg, Still's disease, OA & pain eg, muscular, traumatic & dental pain, headach...

Indication: Relief of mild to moderate pain including muscular, traumatic, dental pain, headache, post-op, postpartum pain...

2  /  6
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.